Keio Plaza Hotel Tokyo Hosts "Princess Mermaid Sweets Buffet" Commemorating the Fairy Tale Written by Hans Christian Andersen
Keio Plaza Hotel Tokyo, one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host the “Princess Mermaid Sweets Buffet” to commemorate the fairy tale “The Little Mermaid” written by the Danish author Hans Christian Andersen. This buffet will offer specially prepared desserts patterned after various sea creatures reminiscent of characters from The Little Mermaid fairy tale, and be held at the All Day Dining restaurant “Jurin” on the second floor of our Hotel from July 1 to September 30, 2017.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170622005536/en/
Keio Plaza Hotel Tokyo's "Princess Mermaid Sweets Buffet" will offer desserts patterned after various sea creatures reminiscent of characters from The Little Mermaid fairy tale. (Photo: Business Wire)
This year’s desserts will represent an even wider variety of sea creatures than last year’s event, and includes tarts reminiscent of cute “hermit crabs” using waffle cones in the shape of conch shells, bread made to look like seals, cream puffs patterned after fish, and moray eel shaped rolled cakes amongst others. Also, special “Blue Mermaid Jelly” using Blue Hawaii flavored gelee, and macaroons made to look like mother of pearl oysters matching the mood of the summer season will be served to guests.
During July, we will also prepare special foods made from watermelon, which is one of the most popular fruits eaten in Japan during the summer, for the enjoyment of our repeat guests. These seasonal desserts and beverages include watermelon and strawberry tart, watermelon fruit punch and other refreshing menu items.
Our All Day Dining restaurant “Jurin” is known for its specially prepared seasonal meals based upon various fairy tales including “Alice’s Adventures in Wonderland” and “Peter Rabbit”. Our patissiers will display their talents by creating a wide variety of delicious desserts divided into five different categories on our 15 meter long counter for customers to enjoy every day from 3:00p.m. to 5:30p.m. during the event. This buffet was also held last year, and the various desserts reminiscent of characters from “The Little Mermaid” was very well received. In addition, we also offer special wedding plans based upon “The Little Mermaid” to expand the range of guests who can enjoy participating in this themed event.
“Princess Mermaid Dessert Buffet”
|Date:||From July 1 to September 30, 2017|
|Time:||3:00p.m. to 5:30p.m.|
|Fees:||JPY 3,800 per adult|
JPY 2,600 per child
Keio Plaza Hotel Tokyo
Keiko Kawashima, +81-3-5322-8010
Public Relations Manager
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43 | Pressemelding
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00 | Pressemelding
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00 | Pressemelding
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00 | Pressemelding
Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom